Syncom Formulation (India) (BOM:524470) Long-Term Debt: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524470 Syncom Formulation (India) Ltd BOM:524470
86 GF Score
Price ₹16.14
GF Value ₹20.44
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Syncom Formulation (India) Long-Term Debt?

Syncom Formulation (India) BOM:524470 +4.26% 86 Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:524470 with a GF Score™ of 86/100 and a GF Value™ of ₹20.44 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Syncom Formulation (India)'s Long-Term Debt for the quarter that ended in Jun. 2026 was ₹0 Mil.

Syncom Formulation (India)  (BOM:524470) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Syncom Formulation (India) Long-Term Debt Related Terms

Syncom Formulation (India) Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Syncom Formulation (India)'s Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syncom Formulation (India) Long-Term Debt Chart

Syncom Formulation (India) Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Syncom Formulation (India) Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:524470
86GF Score
Syncom Formulation (India) Ltd BOM:524470
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of ₹0 Mil mean?
Syncom Formulation (India) (BOM:524470) has a Long-Term Debt of ₹0 Mil as of Jun. 2026.
Is Syncom Formulation (India)'s Long-Term Debt too high?
Syncom Formulation (India)'s current Long-Term Debt is ₹0 Mil. Overall, Syncom Formulation (India) has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syncom Formulation (India)'s Long-Term Debt compare to ZTS?
Syncom Formulation (India)'s Long-Term Debt of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Drug Manufacturers company?
A good Long-Term Debt depends on the Drug Manufacturers industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Syncom Formulation (India)'s current Long-Term Debt is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syncom Formulation (India) stock overvalued right now?
Based on GuruFocus' analysis, Syncom Formulation (India) (BOM:524470) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹20.44, compared to a current price of ₹16.14 — trading 21% below its estimated fair value. The current Long-Term Debt is ₹0 Mil. Syncom Formulation (India)'s overall GF Score™ is 86/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Syncom Formulation (India) (BOM:524470), the current Long-Term Debt is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Syncom Formulation (India) (BOM:524470) Overvalued in 2026?

Based on GuruFocus' analysis, Syncom Formulation (India) stock appears to be undervalued. The current stock price of ₹16.14 is trading 21% below its estimated GF Value™ of ₹20.44. GuruFocus considers Syncom Formulation (India) to be Modestly Undervalued.

Key valuation signals for BOM:524470:

  • Long-Term Debt: ₹0 Mil
  • GF Value™: ₹20.44 vs. price of ₹16.14 (21% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the BOM:524470 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Syncom Formulation (India) Business Description

Other Exchanges SYNCOMF:India
Address 207, Saket Nagar, Near Saket Club, Indore, MP, IND, 452018
Syncom Formulation (India) Ltd is in the business of pharmaceuticals. The company operates through three segments including manufacturing and dealings in Pharmaceutical drugs and formulations, Trading of commodities, and Renting of property. It manufactures and markets pharmaceutical formulation products in various dosage forms like tablets, capsules, liquids orals, liquids vials, ampoule injections and dry vial injections, dry syrups, ointments, inhalers, and Herbals. The company's product includes generic, antiviral, antidepressant, cough suppressant, electrolyte, histamine, estrogen, and much more. It generates maximum revenue through the Pharmaceutical drugs and formulations segment.
86GF Score

Get the complete analysis for BOM:524470

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹16.14
Price
₹20.44
GF Value